Chronokinetic study of cefalexin in postprandial and fasting volunteers

Ding, Yi; Jia, Yi‐Xia; Liu, Wenxing; Lu, Chengtao; Zhu, Yanrong; Yang, Jing; Ding, Likun; Yang, Lin; Wen, Aidong

doi:10.1080/09291016.2011.605639

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study narrated a 1.9-fold decrease in C max of cephalexin and cefroxadin in the fed state as compared to the fasting state after the administration of a similar dose of 250 mg [ 25 ]. In addition, AUC 0-inf was found to be slightly decreased in the postprandial state in two clinical studies, one of which was conducted in adults on cephalexin [ 24 ] and the other in infants and pediatrics comparing the PK of cephalexin, cephradine, cefaclor, and cefadroxil, whose values can be discerned in Table 5 [ 35 ].…”

Section: Resultsmentioning

confidence: 99%

“…Both cephalosporins (cephalexin and cefroxadin) showed a significant decrease in C max in the fed state, depicting delayed absorption in the gastrointestinal tract [ 25 ]. One study reported a greater C max of cephalexin at the 20th hour than at the 8th hour after the intake of food, which may show the effect of time in the postprandial state as compared to the fasting condition [ 24 ]. In another study, the effect of food on cephalexin and cephradine was promptly indicated by a decrease in C max and AUC 0-inf in comparison to cefadroxil and cefaclor, which may be due to changes in PK features of the latter that were considered to be the predecessors of the former [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Systematic Review on the Clinical Pharmacokinetics of Cephalexin in Healthy and Diseased Populations

Kanan,

Atif,

Mohammed

et al. 2023

Antibiotics

View full text Add to dashboard Cite

Cephalexin is a first-generation β-lactam antibiotic used in adults and pediatrics to treat various streptococcal and staphylococcal infections. This review aims to summarize and evaluate all the pharmacokinetic (PK) data on cephalexin by screening out all pertinent studies in human beings following the per oral (PO) route. By employing different online search engines such as Google Scholar, PubMed, Cochrane Central, and Science Direct, 23 studies were retrieved, among which nine were in healthy subjects, five in diseased ones, and the remaining were drug–drug, drug–food, and bioequivalence-related. These studies were included only based on the presence of plasma concentration-time profiles or PK parameters, i.e., maximum plasma concentration (Cmax), half-life (t1/2) area under the curve from time 0-infinity (AUC0–∞), and clearance (CL/F). A dose-proportional increase in AUC0–∞ and Cmax can be portrayed in different studies conducted in the healthy population. In comparison to cefaclor, Cmax was recorded to be 0.5 folds higher for cephalexin in the case of renal impairment. An increase in AUC0–∞ was seen in cephalexin on administration with probenecid, i.e., 117 µg.h/mL vs. 68.1 µg.h/mL. Moreover, drug–drug interactions with omeprazole, ranitidine, zinc sulfate, and drug–food interactions for cephalexin and other cephalosporins have also been depicted in different studies with significant changes in all PK parameters. This current review has reported all accessible studies containing PK variables in healthy and diseased populations (renal, dental, and osteoarticular infections, continuous ambulatory peritoneal dialysis) that may be favorable for health practitioners in optimizing doses among the latter.

show abstract

Section: Resultsmentioning

confidence: 99%